Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
07:05am, Thursday, 28'th May 2026
NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
11:05am, Friday, 22'nd May 2026
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
12:56pm, Tuesday, 12'th May 2026
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 05'th May 2026
ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligibl
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
09:05am, Tuesday, 28'th Apr 2026
Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 millio
Protagonist Therapeutics Reports Granting of Inducement Awards
04:05pm, Thursday, 16'th Apr 2026
NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accor
SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX
05:03am, Monday, 06'th Apr 2026
SG Americas Securities LLC reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 51.5% in the undefined quarter, according to the company in its most recent filing with the SEC. The
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results fur
Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi
08:45am, Tuesday, 24'th Mar 2026
Protagonist Therapeutics earns a Buy rating, driven by Icotyde's FDA approval and robust near-term commercialization catalysts. Icotyde, the first oral IL-23 receptor antagonist for plaque psoriasis,
Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone
02:02am, Monday, 23'rd Mar 2026
Protagonist Therapeutics (NASDAQ: PTGX) executives said March 18 that the U.S. Food and Drug Administration has approved ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
01:01pm, Friday, 20'th Mar 2026
PTGX stock jumps as JNJ wins FDA nod for Icotyde in plaque psoriasis, unlocking milestone payments and royalty potential for Protagonist.
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
10:06am, Friday, 20'th Mar 2026
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further pri
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript
03:52pm, Wednesday, 18'th Mar 2026
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
08:05am, Wednesday, 18'th Mar 2026
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met
